Erschienen in:
30.09.2019 | Translational Research and Biomarkers
High Stromal TGFBI in Lung Cancer and Intratumoral CD8-Positive T Cells were Associated with Poor Prognosis and Therapeutic Resistance to Immune Checkpoint Inhibitors
verfasst von:
Nobuhiro Nakazawa, MD, Takehiko Yokobori, MD, PhD, Kyoichi Kaira, MD, PhD, Andrei Turtoi, PhD, Seded Baatar, MD, Navchaa Gombodorj, PhD, Tadashi Handa, MS, Mariko Tsukagoshi, MD, PhD, Yasunari Ubukata, MD, Akiharu Kimura, MD, PhD, Norimichi Kogure, MD, PhD, Kyoichi Ogata, MD, PhD, Toshitaka Maeno, MD, PhD, Makoto Sohda, MD, PhD, Toshiki Yajima, MD, PhD, Kimihiro Shimizu, MD, PhD, Akira Mogi, MD, PhD, Hiroyuki Kuwano, MD, PhD, FACS, Hiroshi Saeki, MD, PhD, FACS, Ken Shirabe, MD, PhD, FACS
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 3/2020
Einloggen, um Zugang zu erhalten
Abstract
Background
We investigated whether the expression of transforming growth factor-beta-induced protein (TGFBI) and intratumoral immune cells including CD8- and Forkhead box protein P3 (Foxp3)-positive T cells in clinical lung cancer patients could predict the therapeutic response to nivolumab.
Methods
Thirty-three patients who were treated with nivolumab were enrolled in this study. Immunohistochemical analyses of TGFBI, PD-L1, CD8, Foxp3, and vimentin expression were conducted. Serum concentrations of TGFBI and transforming growth factor-beta1 (TGF-β1) were determined by enzyme-linked immunosorbent assay (ELISA).
Results
Cancer TGFBI was not associated with prognosis and therapeutic response to nivolumab, but cancer stromal TGFBI and intratumoral CD8-positive T cells were associated with them. Therefore, we evaluated cancer stromal TGFBI and intratumoral CD8-positive T cells. The high-TGFBI-expression group had poorer clinical responses than did the low-TGFBI-expression group (p < 0.0001). The number of times nivolumab was administered in the high-CD8-expression group was significantly higher than that in the low-CD8-expression group (p = 0.0046). The high-CD8-expression group had better clinical responses than did the low-CD8-expression group (p = 0.0013). Interestingly, all patients in the high-TGFBI/low-CD8-expression group had progressive disease (PD). In contrast, all patients in the low-TGFBI/high-CD8-expression group had PR + SD (partial response + stable disease) by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Conclusions
The dual evaluation of stromal TGFBI and intratumoral CD8-positive T cells could be a useful predictive marker for nivolumab.